Quick verdict
- What it is
- Store information collected; independent summary not yet available.
- At a glance
-
- Free download · core features require a paid plan
- In-app purchases
- From $1.66/mo
Categories and search queries
Official categories
- Medical
- Reference
AppCorpus categories
Key functions
| Function | Availability | Access | Scope | Evidence |
|---|---|---|---|---|
| Family Sharing | Yes | Unknown | App Store | Store published |
| Free app | Yes | Free | — | Store published |
| In-app purchases | Yes | Limited free | — | Store published |
| Subscription | Yes | Paid | — | Store published |
Screens
App Store
34 store screenshots
Pricing & paywalls
App Store
- Subscription — $19.99/year ($1.66/mo) (derived from the IAP title)
Ratings & reviews
App Store
No store reviews collected for App Store · US
Privacy & accessibility
App Store
Privacy
- Data Not Collected Developer declared
Accessibility
No accessibility labels collected yet.
Versions
App Store
-
26.10
• Inclusion of the SOFA-2 score (updated SOFA) and the AURIS score (C. auris candidemia). • Changes in daptomycin, fluconazole, gentamicin, ibrexafungerp, isavuconazole, oteseconazole, posaconazole, sertaconazole, teicoplanin, voriconazole. Bacillus anthracis, Clostridioides difficile, Legionella, Mycobacteroides chelonae, Mycoplasma pneumoniae, Pluralibacter, Staphylococcus aureus, Treponema pallidum; Candida, Coccidioides, Gloniopsis, Talaromyces; Oestrus ovis. Pneumonia. Sepsis and septic shock. Vaginitis. Recurrent vulvovaginal candidiasis.
-
26.11
• Inclusion of the tetanus severity score (TSS). • Changes in carbapenems, cefepime, cefepime/enmetazobactam, faropenem, fostemsavir, gepotidacin, omadacycline, penicillins. Acinetobacter, Mycobacterium tuberculosis, Mycobacteroides chelonae, Pseudomonas aeruginosa, Streptococcus pneumoniae; Aspergillus, Candida, Cryptococcus neoformans, Mucor, Pneumocystis jirovecii, Trichophyton; HSV-1, SARS-CoV-2. Encephalitis. Infectious arthritis. Intravenous catheter infection. Neutropenic fever and in HSCT recipients. Pneumonia. Sepsis and septic shock. COVID-19 vaccination. Prophylaxis of invasive fungal disease. RSV vaccination. VEXAS syndrome (infection prevention).
-
26.12
Changes in dalbavancin. BCG, Clostridioides difficile, Enterococcus, Fusobacterium, Mycobacterium tuberculosis, Neisseria meningitidis, Roseomonas, Staphylococcus aureus; Candida; Trypanosoma cruzi. Biomarkers of inflammation/infection. Neutropenic enterocolitis. Pneumonia. Sepsis and septic shock. Vaginitis. Meningococcal meningitis (prevention). Recurrent vulvovaginal candidiasis. Surgical site infection (prophylaxis). Tuberculosis prevention.
-
26.13
Changes in ciprofloxacin, daptomycin, gepotidacin, oritavancin, quinolones, zoliflodacin. Helicobacter, Mycobacterium tuberculosis; Aspergillus, Schizophyllum; influenza. Infective endocarditis. Pleural effusion of infectious origin. Prosthetic joint infection. Sepsis and septic shock. Sinusitis. Toxic shock syndrome. Urethritis. Chikungunya vaccination. Infections associated with immunosuppressive therapies (prophylaxis). Infective endocarditis (prophylaxis). Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Surgical site infection prevention.
-
26.14
Changes in cefepime, dalbavancin, daptomycin, doxycycline, eravacycline, isavuconazole, linezolid, quinolones. Acinetobacter, Anaplasma, Bacillus spp, Bartonella, Borrelia burgdorferi, Corynebacterium, Mycoplasma spp, Stenotrophomonas, Treponema pallidum; Aspergillus, Candida, Coccidioides, Pneumocystis jirovecii, Rasamsonia; EBV, HBV, YFV. Brain abscess. Infectious endocarditis. Pancreatic infections. Lyme disease prevention.
-
26.15
Changes in aztreonam/avibactam, bedaquiline, clofazimine, contezolid, dihydroartemisinin/piperaquine, glycopeptides, linezolid, meropenem/vaborbactam, molnupiravir, nirmatrelvir/ritonavir, penicillins, rifabutin. Acinetobacter, Klebsiella, Pseudomonas aeruginosa; Candida; influenza, MPXV, norovirus. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Pneumonia. Sepsis and septic shock. Influenza vaccination. Recurrent urinary tract infection. Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Venous catheter infection (prevention).
-
26.16
Changes in amoxicillin/clavulanate, amphotericin B (liposomal and deoxycholate), cabotegravir, ceftazidime/avibactam, posaconazole, quinolones, rilpivirine. Klebsiella, Pseudomonas aeruginosa; Aspergillus, Candida, Cryptococcus neoformans; Trypanosoma cruzi. Bacterial prostatitis. Cystitis. Infective endocarditis. Osteomyelitis. Prosthetic joint infection. Skin, subcutaneous tissue, and fascia infections. Toxic shock syndrome. Chikungunya vaccination. Dengue vaccination. Human papillomavirus vaccination. Infections in neutropenic patients (prevention). Pertussis prevention. Pertussis vaccination. RSV vaccination.
-
26.17
• Added the DENOVi score (E. faecalis bacteremia). • Changes in amoxicillin, amoxicillin/clavulanate, cabotegravir, imipenem/relebactam, isavuconazole, linezolid, meropenem/vaborbactam, posaconazole, sulbactam/durlobactam, voriconazole. Clostridioides difficile, Enterococcus, Escherichia coli, Leptospira, Staphylococcus aureus, Streptobacillus moniliformis; Aspergillus, Sporothrix; influenza; Plasmodium falciparum. Cervicitis. Exacerbations of COPD. Prosthetic joint infection. Treatment of β-lactam-resistant Enterobacterales infections. COVID-19 vaccination. Influenza (chemoprophylaxis). Infections in solid organ transplant recipients (prevention).
-
26.18
Changes in cefiderocol, colistin, gepotidacin, imipenem/relebactam, lenacapavir, olorofim. Bacteroides, Citrobacter, Enterococcus, Providencia, Staphylococcus aureus, Streptococcus agalactiae; Candida; dengue, NiV, rhinovirus, RSV, SARS-CoV-2. Guillain-Barré syndrome. Pleural effusion of infectious origin. Sepsis and septic shock. Malaria (prevention). Surgical site infection (prevention).
-
26.19
Changes in anidulafungin, bedaquiline, ganciclovir, imipenem/relebactam, micafungin, omadacycline, pretomanid, voriconazole. Clostridioides dificile, CoNS, Gordonia, Mycobacterium kansasii, Mycobacterium tuberculosis, Paenibacillus, Staphylococcus aureus; Aspergillus, Cryptococcus neoformans and C. gattii; HIV, Orthohantavirus, RSV, YFV. Brain abscess. Infections of the spine. Respiratory infections in cystic fibrosis. Sepsis and septic shock. Sinusitis. Recurrent urinary tract infection. Surgical site infection (prophylaxis).
-
26.20
Changes in amphotericin B deoxycholate, bictegravir, daptomycin, tecovirimat. Butyricimonas, CoNS, Escherichia coli, Gardnerella, Haemophilus influenzae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Shewanella, Staphylococcus aureus, Streptococcus agalactiae; Arthrographis kalrae, Candida, Trichophyton; LASV, MPXV, SARS-CoV-2, WNV; Sarcoptes scabiei, Schistosoma. Acute meningitis. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Infections of the eyelid. Sepsis and septic shock. Infections in solid organ transplant recipients (prevention). Influenza vaccination. RSV prevention.
-
26.21
• Added Dermatophilus congolensis (under Pathogens). • Changes in azithromycin, aztreonam/avibactam, cefepime/taniborbactam, cefiderocol, colistin, isoniazid. Enterobacter, Mycobacterium chelonae, Pseudomonas aeruginosa, Shigella, Streptococcus pneumoniae; CMV, EBOV, Mpox, SARS-CoV-2. Encephalitis. Exacerbations of COPD. Facial palsy. Peritonitis. Treatment of β-lactam-resistant Enterobacterales infections.
-
26.22
• Added a new entry on infections in patients with major burns (under Syndromes). • Changes in bictegravir, cabotegravir, cefiderocol, ensitrelvir, ertapenem, nitrofurantoin, pristinamycin, zoliflodacin. Chlamydia psittaci, Mycobacterium xenopi, Mycoplasma genitalium, Neisseria gonorrhoeae, Pseudomonas aeruginosa; Diutina, Purpureocillium; CMV, JCPyV, KFDV, RSV, SARS-CoV-2; Echinococcus granulosus, Leishmania. Biomarkers of inflammation/infection. Infections during CAR T-cell therapy. Pneumonia. CMV prophylaxis. RSV prevention. RSV vaccination. Tuberculosis prevention.
-
26.23
• Added a PaO₂ estimation calculator (from SpO₂). • Changes in cefiderocol, ceftriaxone, dalbavancin, eravacycline, isoniazid, tigecycline. Enterococcus, Mycobacterium tuberculosis, Pneumocystis jirovecii; CMV, SARS-CoV-2; Babesia. Prosthetic joint infection. Viral hemorrhagic fevers. CMV prophylaxis. HPV vaccination. RSV vaccination. Shingles (herpes zoster) vaccination. Surgical site infection prophylaxis. Toxoplasma gondii (prevention in hematologic patients).
-
26.24
• Added bepirovirsen and cefepime/zidebactam to Antimicrobials. • Changes in fosmanogepix, ibrexafungerp, maribavir, olorofim, and ECOFF values (aztreonam/avibactam). Sphingomonas, Stenotrophomonas; Aspergillus, Candida; CMV, Ebola, EBV, HBV, MPXV; Plasmodium falciparum. Infections in patients with liver cirrhosis. Pneumonia. Prosthetic joint infection. Asymptomatic bacteriuria (UTI prevention). RSV vaccination. Venous catheter infection (prevention).
-
26.25
• Added MAGIC criteria for VGEI to Utilities. • Changes in amoxicillin, bedaquiline, colistin, dalbavancin, fluconazole, levofloxacin, olorofim, voriconazole, zanamivir. Acinetobacter, Burkholderia pseudomallei, Clostridium spp, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas, Streptococcus gallolyticus, Treponema pallidum; Lomentospora, Mucor, Scedosporium; HHV-6, influenza, OROV. β-lactam-resistant Enterobacterales infections. Biomarkers of inflammation/infection. Sepsis and septic shock. Infections in neutropenic patients (prevention). Influenza vaccination. Surgical site infection prevention. Venous catheter infection prevention.
-
26.25.1
Minor bug fixes, including a correction to the MAGIC criteria evaluation.
-
26.26
Changes in benzylpenicillin, cefazolin, eravacycline, gepotidacin, imipenem/relebactam, liposomal amphotericin B, posaconazole, remdesivir, ribavirin, tafenoquine, temocillin. Acinetobacter, Clostridioides difficile, Enterobacter, Fusobacterium, Klebsiella, Mycobacterium tuberculosis, Staphylococcus aureus, Stenotrophomonas; Pneumocystis jirovecii, Trichophyton; HPIV, MARV; Blastocystis. Abscesses (intra-abdominal, anorectal, and prostatic). β-lactam-resistant Enterobacterales infections. Pneumonia. Pyelonephritis. Infections associated with immunosuppressive therapies (prophylaxis). Prophylaxis of invasive fungal disease in onco-hematologic patients.
-
26.27
Changes in azithromycin, molnupiravir, piperacillin/tazobactam, zoliflodacin. Burkholderia pseudomallei, Mycobacterium avium, Neisseria gonorrhoeae, NTM, Pseudomonas aeruginosa, Rickettsia prowazekii, Tropheryma whipplei; Candida, Lacazia loboi; enterovirus, HBV, influenza, Orthonairovirus, RSV, SARS-CoV-2, VZV. Bacterial prostatitis. Cystitis. Neutropenic fever. Osteomyelitis. Prosthetic joint infection. Sepsis and septic shock. Infections in SOT recipients (prevention).
-
26.28
Changes in azithromycin, aztreonam, cefazolin, cefepime/enmetazobactam, ceftazidime, ceftibuten, cloxacillin, daptomycin, letermovir, linezolid, minocycline. Acinetobacter, Elizabethkingia, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Serratia, Streptococcus pneumoniae, Streptococcus pyogenes; Aspergillus; YEZV; free-living amoebae. β-lactam-resistant Enterobacterales infections. Biomarkers of inflammation/infection. Infective endocarditis. Osteomyelitis. Pneumonia. Prosthetic joint infection. Sepsis and septic shock. Chronic bronchitis, COPD (prevention of exacerbations).
-
26.29
Changes in cefepime, olorofim, tedizolid, temocillin, tenofovir. Actinomyces, Bartonella, Campylobacter, Clostridioides difficile, Cutibacterium, NTM, Streptococcus other spp; Aspergillus, Candida; CHIKV, HCV, hMPV, influenza; Plasmodium falciparum. Appendicitis. Fever of unknown origin in immunocompetent patients. Odontogenic infections and periodontal disease. Viral hemorrhagic fevers. Surgical site infection prevention.
-
26.30
Changes in dolutegravir, linezolid, oritavancin. Burkholderia pseudomallei, Clostridioides difficile, Clostridium spp, Haemophilus influenzae, Haemophilus spp, Peribacillus, Staphylococcus aureus, Treponema pallidum; Candida; JCPyV, measles, Orthohantavirus. Fever of unknown origin in immunocompetent patients. Infective endocarditis. Postoperative fever. Skin, subcutaneous tissue, and fascia infections. Toxic shock syndrome. Vascular graft or endograft infection. CDI prevention.
-
26.31
· 2 Aug 2026
Changes in cefazolin, eravacycline, meropenem, rezafungin, sulbactam/durlobactam. Borrelia burgdorferi, Enterococcus, Mycobacterium tuberculosis, Pseudomonas aeruginosa; Medicopsis romeroi, Pneumocystis jirovecii; BRPV, HCV, SFTSV, TBEV, VZV. Allergy to antibiotics. Biomarkers of inflammation/infection. Fever and rhabdomyolysis. Healthcare-associated meningitis and ventriculitis. Prosthetic joint infection. Sepsis and septic shock. Skin, subcutaneous tissue, and fascia infections. STD prevention. Surgical site infection prophylaxis.
-
26.8
Changes in acyclovir, amikacin, ceftazidime/avibactam, zoliflodacin. Clostridium tetani, Cryptococcus neoformans, Franklinella schreckenbergeri, Legionella, Leptospira, Neisseria meningitidis, Spodiobacter cordis, Vandammella animalimorsus; Apophysomyces, Cunninghamella, Mucor, Pythium, Saksenaea; EBV, HIV, MPXV, RSV; Plasmodium spp. Allergy to antibiotics. Fever in neutropenic patients. Infections of the spine or spinal implants. Pyelonephritis. Sepsis and septic shock. Treatment of β-lactam-resistant Enterobacterales infections. HIV infection prophylaxis. Premature rupture of membranes (infection prevention). Surgical site infection prophylaxis. Tetanus vaccination.
-
26.9
• Inclusion of a linezolid TDM predictive score for identifying out-of-range exposure risks. • Changes in aztreonam/avibactam, dapsone, daptomycin, gepotidacin, itraconazole, meropenem, posaconazole, tecovirimat. Borrelia burgdorferi, Klebsiella, Lactobacillus, Leptospira, Mycobacterium leprae, Neisseria meningitidis, Staphylococcus aureus, Streptococcus agalactiae; Candida; HCV, HDV, MPXV. Exacerbations of COPD. Fever and rash. Odontogenic infections. Pharyngotonsillitis. Pneumonia. Sepsis and septic shock. Group B streptococcus (prevention of maternal and neonatal infection). Infections associated with immunosuppressive therapies (prophylaxis). RSV vaccination.
Alternatives
- enGuardia — Same category + similar ratings
- Urgencias Pediatría GIDEP WEST — Same category + similar ratings
- eMPendium — Same category + similar ratings
- Manuales AMIR 2.0 — Same category + similar ratings
- iDoctus — Same category + similar ratings
- iDoctus Pediatría — Same category + similar ratings
Availability by market
- US
Data quality & evidence
- Page completeness
- Live store listing
- Last verified
- 7 Aug 2026
- Sources
- App Store
- Independent summary has not been published yet.